lower respiratory tract infection Pneumonia
Conditions
Interventions
Subjects will be assigned to 6 mg dexamethasone starting dose administered PO,
followed by 3 times 6 mg dexamethasone PO once daily or
5,26 mg dexamethasonedisodiumphosphate (= 4 mg dexamethasone) st
Sponsors
Sint Antonius Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Aged 18 years and older - Presenting to the emergency room with suspected pneumonia (to be confirmed within 24 hours from admission) - Pneumonia is defined as a new or progressive infiltrate on a chest X-ray plus at least two of the following criteria: cough, sputum production, temperature >38°C or <35°C, ausculatory findings consistent with pneumonia, leucocytosis or leucopenia (>10 g/l, <4 g/l or >10% rods in leucocyte differentiation), C-reactive protein >3 times the upper normal limit - Corticosteroid naive at time of presentation
Exclusion criteria
Exclusion criteria: - Patients needing corticosteroid treatment above study medication - Failure to obtain written consent to participate - Patients using fenytoine, barbiturates, rifampicine, erythromycin, clarithromycine, aprepitant, colchicine, everolimus, itraconazol, ketoconazole, pazopamib, tipranavir, vinorelbin - Moribund patients (defined as expected to die within 24 hours) - Patients with proven or suspected allergy to dexamethasone - Patient not capable of taking tablets orally
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Extent of exposure reflected by the area under concentration time curve (AUC0-24) | — |
Secondary
| Measure | Time frame |
|---|---|
| Cmax, Tmax and Ctrough | — |
Countries
Netherlands
Outcome results
None listed